Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.
Publication
, Journal Article
Heimberger, AB; Archer, GE; McLendon, RE; Price, D; Friedman, AH; Friedman, HS; Bigner, DD; Sampson, JH
Published in: CLINICAL CANCER RESEARCH
November 1, 2000
Duke Scholars
Published In
CLINICAL CANCER RESEARCH
ISSN
1078-0432
Publication Date
November 1, 2000
Volume
6
Start / End Page
4542S / 4543S
Publisher
AMER ASSOC CANCER RESEARCH
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Heimberger, A. B., Archer, G. E., McLendon, R. E., Price, D., Friedman, A. H., Friedman, H. S., … Sampson, J. H. (2000). Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH, 6, 4542S-4543S.
Heimberger, A. B., G. E. Archer, R. E. McLendon, D. Price, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.” CLINICAL CANCER RESEARCH 6 (November 1, 2000): 4542S-4543S.
Heimberger AB, Archer GE, McLendon RE, Price D, Friedman AH, Friedman HS, et al. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH. 2000 Nov 1;6:4542S-4543S.
Heimberger, A. B., et al. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.” CLINICAL CANCER RESEARCH, vol. 6, AMER ASSOC CANCER RESEARCH, Nov. 2000, pp. 4542S-4543S.
Heimberger AB, Archer GE, McLendon RE, Price D, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2000 Nov 1;6:4542S-4543S.
Published In
CLINICAL CANCER RESEARCH
ISSN
1078-0432
Publication Date
November 1, 2000
Volume
6
Start / End Page
4542S / 4543S
Publisher
AMER ASSOC CANCER RESEARCH
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis